		,									D
type a plus s	ign (+)	inside this	$box \rightarrow \boxed{+}$] ,		S. Pate	Approved	d for use k Office:	through 10/3 U.S. DEPAR it contains a va	PTO/SB/08A (08-00 1/2002. OMB 0651-003 IMENT OF COMMERCI alid OMB control number	<u> </u>
r the Paperwo	rk Red	uction Ac	t of 1995, no pe	erso ns are re	ouired to re	spood to a collect	Co.	mpl t	e if Kn wn	alid OMB control number	14
		orm 1449 <i>F</i>		12		Application		09	7700 07	4 7 3	5 6
				1 0 S	RE	Filing Date	Mulliber	10	/13/200	C	到と
INF)KI		T DV VE	DI ICA	NT	First Name	d Inventor	Je	ffrey A	Ledberter	4 [
STA	TE	MFN	T BY AF	PLICA		Group Art l	Jnit	 			一孔,
	(use	as many	y sheets as n	ecessary)		Examiner N				3	1
Shoot		1	of	3		Attorney Do	ocket Number				
Sheet									<u> </u>	- C	
					U.S. P	TENT DOCU	MENTS	ion of	Pag	es, Columns, Lines,	>
		U.S. Pa	itent Document		of Patente	e or Applicant	Date of Publication Cited Document	ent	Pa	Where Relevant ssages or Relevant	l
C. A. C. L. L. L. C. L.	ite -	Number	Kind Cod	e² l	of Cited Do	ocument	MM-DD-YYY	Y Y +	07 21-70	Figures Appear 06.34-65, p.9 2-	7
This die		\$ 5962	(If Known	Armit	age e	t al.	10/5/9	9-1	2 21-28	16.34-65,p9.2.	7
 	- <u> </u>	15598	1724	Armit	age e	t al.	7/30/9	6	08.1-59	P11.48-56	
	 	IS 554	0926	Aruff	o et	<u>al</u>	12/16/	97 li	Fiz1, p3.1-8	1,p4.1-6,p6.1-16, p	6.53-65,
	_ h	IS 5 69	8 <u>679</u>	Nemas	zee et	4 07	7/11/0	0	03.40-67,8	4.1-8, p4.66-61, p	<u>5.1-18</u>
		IS608	6875	Blum	perg e	tal.	8/19/9	7	P1.13-20	1	
	1	US 565	8762	Zane	tti et	et al.	9/15/0	00	Fig. 1B, F	1 1/2 1C, p.7 lines 38-6	<u>ιτ ρ.</u> Β ινα
		US611	3901_	Blue	SLOWS						
 +											
 									 		
 											
							_				
									<u> </u>		
		<u> </u>							 		
 		 							 		
 		 							 		
		 							 		
					FORE	GN PATENT	DOCUMENTS	<u> </u>			
				ant Documer		Name of P	10	Date of I	Publication of	Pages, Columns, Lines, Where Relevant	1 1
Examiner	Cite			ent Documer K	ind Code ³	Applicant of Ci	ted Document	Cited MM-	Document DD-YYYY	Passages or Relevant Figures Appear	T ⁶
Initials'	No.1	Office ³	Numbe	er (if known)						
					-++						
											-+
			 								
 			 					 			
0000 rug	0004	V96878	34 >					 			
	+		80,00 DP					 			
	+-							 			
 	1							+		•	
·											

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->
--

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperw	vork Reduction Ad	ct of 1995,	no persons are equired to res	spond (collection of information	n unless it contains a valid OMB control number.
Substitute	e for form 1449B/	PTO	RADE	C	mplete if Known
				Application Number	09/687,864
INFC	PRMATIC	ON D	ISCLOSURE	Filing Date	10/13/2000
STA	TEMEN	r BY	APPLICANT	First Named Inventor	Jeffrey A. Ledbetter
•			,	Group Art Unit	
	(use as mai	ny sheets	s as necessary)	Examiner Name	
Shoot	2	of	3	Attorney Docket Number	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	T
ixaminer nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
		HOWELL, A.L., ET AL., "Targeting HIV-1 to FcgammaR on human	
		phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells." J. of Leuk. Biol. 55: 385-391 (1994).	
		-HIV-1 - CO I COLLEY - J. OI - DEUR DIVIA J.	
<u></u>		ZAGHOUANI, H., ET AL., "Induction of antibodies to the human	
		immunodeficiency virus type I by immunization of baboons with	
		immunoglobulin molecules carrying the principal neutralizing	┢
		determinant of the envelope protein." PNAS 92: 631-635 (1995)	ľ
		SYRENGELAS, A.D., ET AL., "DNA Immunization induces protective	T
		immunity against B-cell lymphoma." Nature Med. 2: 1038-1041 (1996).	L
		LIU, C., ET AL., "Fcgamma RIII on Human B Cells Can Mediate Enhanced Antigen Presentation." Cell. Immunol. 167: 188-194.	
		LIU, C., ET AL., "FcgammaRI-Targeted Fusion Proteins Result in	
		Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes." J. Clin. Invest. 98: 2001-2007.	
		(1996).	
		GUYRE, P.M., ET AL., "Increased Potency of Fc-receptor-targete antigens." Cancer Immunol. Immunother. 45: 146-148 (1997).	đ

	William Control		
Examiner		Date	
Signature		Consid r d	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → + FEB 2 Under the Paperwork Reduction Act of 1995, no persons are expired to res	Approve atent and Tradema pond to a collection of information	PTO/SB/08B (08-00) and for use through 10/31/2002. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE of unless it contains a valid OMB control number.	+
Under the Paperwork Reduction Act of 1995, no persons are sales	Col	mpl te if Known	多分
Substitute for form 1449B/PTO	Application Number	09/687.864	
INFORMATION DISCLOSURE	Filing Date	10/13/2000	0 2
INFORMATION DISOLUCIANT	First Named Inventor	Jeffrey A. Ledhetter	10 0 T
STATEMENT BY APPLICANT	Group Art Unit		
(use as many sheets as necessary)	Examiner Name		18
3, 0,	Attorney Docket Number		30,200
Sheet ~ (0)			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	T2
xaminer	Cite	OTHER PRIOR ART — NON TANDER OF THE ART — NON TANDER O	T ²
itials*	No. ¹	a marron cos to a INA vaccine	
		BOYLE, J.S., ET AL., "Enhanced responses to a line of immune encoding a fusion antigen that is directed to sites of immune induction." Nature 392: 408-411 (1998).	-
			<u></u>
		GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines Res. Immunol. 149: 655-660 (1998).	
		SERRE, K., ET AL., "Efficient Presentation of MultivalentAntia Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen-Specific B Cells." J. Immunol. 161	gen:
	+-	6059-6067. (1998).	
		RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-22	
		(4000)	+
		BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a sell BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a sell dependent antitumor	
-	-	tumor antigen induces protective, 1-0012 - 1999). immunity." Nature Biotech. 17: 253-258. (1999).	
			+
			\dashv
	_		

	Date
Examiner	Consid red
Signatur	Draw line through citation if not in conformance and

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.